Overview
Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer. The company's alfapump® system is approved in Europe but not yet in Canada for commercial use. DSR® therapy is in development and not yet approved in the United States or Canada.
Media & appearances
- De TijdYouTubeSuperfan Arne Rotsaert: ‘Sommige afleveringen van De Beursvoyeurs beluister ik twee keer'Brussels-listed medtech making ascites pumps for liver patients that went bankrupt after failed commercialization, consecutive capital increases and no buyer or external financing found.
Stated facts & numbers
- Sequana Medical IPO'd on the Brussels exchange in February 2019 at around €8.5 and has now filed for bankruptcy after failed commercialization despite FDA approval. (0:02:36, De Tijd 2026-07-01)
In the news
- Weekly paracentesis procedures can significantly impact overall well-being and quality of life for patients with recurrent or refractory ascites due to liver cirrhosis. Jerry, an alfapump patient, discusses the physical and emotional toll of managing ascites through frequent medical procedures and how this condition affected his energy levels and daily motivation before receiving the alfapump System, an FDA-approved treatment for adults with refractory or recurrent ascites due to liver cirrhosis. Excerpt from full patient story.
- Cirrhosis is late-stage liver disease that occurs when scar tissue replaces healthy liver tissue. While alcohol and viral hepatitis have historically been common causes, cirrhosis is increasingly being driven by obesity and metabolic dysfunction-associated steatohepatitis (MASH) — conditions affecting a growing number of people across the U.S. One of the most serious complications of cirrhosis is ascites, or the buildup of fluid in the abdomen. As the disease progresses, ascites can become resistant to standard treatments, leaving
- The impact of the alfapump System extends beyond the patient. Hear from the daughter of an alfapump patient about what life looked like before and after the pump - from being tied to weekly paracentesis procedures to now being able to travel and take family trips together. Patient and family testimonial represents one individual’s experience. Individual results may vary. IMPORTANT SAFETY INFORMATION: The alfapump® System is intended for single patient use only in adult patients with refractory or recurrent ascites due to liver
- The alfapump System is a fully implantable, battery-powered device designed to automatically and continuously remove fluid from the abdomen into the bladder, where it is simply urinated away. No repeated needle punctures, no external tubes. Once implanted, patients charge the device wirelessly for approximately 20 minutes each day. The pump is programmed by the physician to suit each patient’s routine, and performance data is transmitted to clinicians for remote monitoring. The alfapump received FDA approval in December 2024 and is
- In a recent interview, our CEO Ian Crosbie discusses the alfapump System, the patients we serve, and what it means to be in the U.S. market delivering a modern treatment option for those living with recurrent or refractory ascites due to liver cirrhosis. From the pivotal POSEIDON study to FDA approval and commercial launch, Ian shares the milestones that have shaped Sequana Medical and the vision for making the alfapump the new standard of care. Read the full interview: https://lnkd.in/ekiyfysy For important safety information,
Something wrong or missing? Send an update. Fixed within 24 hours.